Tag: update

ATLANTA, July 08, 2025 (GLOBE NEWSWIRE) -- Gray Media, Inc. (“Gray”) (NYSE: GTN) announced today the pricing of its previously announced private offering of $900 million aggregate principal amount of 9.625% senior secured second lien notes due 2032 (the “Notes”). This represents an increase of $150 million over the amount previously announced. The Notes were priced at 100% of par. The offering of the Notes is expected to close on July 18, 2025, subject to customary closing conditions.

WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of its previously announced underwritten public offering of 22,222,223 shares of its common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering are expected to be approximately $200 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Cogent has granted the underwriters a 30-day option to purchase up to an additional 3,333,333 shares of its common stock on the same terms and conditions. All of the securities in the offering are being sold by Cogent. The offering is expected to close on or about July 10, 2025, subject to the satisfaction of customary closing conditions.

As Consumers Search for the Best Non-Prescription Eye Supplements in 2025, Visium Pro Highlights Clean Label Formulation, GMP Manufacturing, and Ingredient Transparency for Digital Eye Strain and Screen Fatigue Support

Singapore, July 08, 2025 (GLOBE NEWSWIRE) -- Delixy Holdings Limited (the “Company” or “Delixy”), a Singapore-based company engaged in the trading of oil related products, today announced the pricing of its initial public offering (the “Offering”) of 2,000,000 ordinary shares, par value US$0.000005 per share, (“Ordinary Shares”), 1,350,000 of which are being offered by the Company and 650,000 by the selling shareholders Mega Origin Holdings Limited (as to 325,000 Ordinary Shares) and Novel Majestic Limited (as to 325,000 Ordinary Shares) (the “Selling Shareholders”), at a public offering price of US$4.00 per Ordinary Share. The Company is also registering a resale prospectus concurrent with the Offering for the resale of 3,000,000 Ordinary Shares held by Cosmic Magnet Limited, Rosywood Holdings Limited, Dragon Circle Limited and Novel Majestic Limited, Golden Legend Ventures Limited (the “Resale Shareholders”). The Ordinary Shares have been approved for listing on the Nasdaq Capital Market and are expected to commence trading on July 9, 2025 under the ticker symbol “DLXY.”

Transition Accompanies Strong Revenue Growth, Expanded Profitability, and Strengthened Balance Sheet

VANCOUVER, BC, July 08, 2025 (GLOBE NEWSWIRE) -- Carbon Done Right Developments Inc. ("Carbon Done Right" or the "Company") (TSXV: KLX) (FSE: Q1C), a leading provider of high-quality carbon credits sourced exclusively from afforestation and reforestation projects developed and owned by the Company, is pleased to announce the addition of Yang Zhou to its board of directors. The company is finalizing the recruitment of a second board member and will provide an update in the coming weeks. The goal of these new appointments is to strengthen the company’s efforts to secure new carbon projects beyond the current focus on nature based solutions and beyond the primarily tropical geographies where the company is currently active.

Yang Zhou has an interdisciplinary background in finance (CFA), business (MBA), accounting (CICPA), law (JM) and engineering. He has over 18 years of experience as a financial analyst, management consultant, academic researcher, PE fund manager, compliance officer and licensed lawyer. He has extensive experience as an analyst focused on ESG, Impact Investing and carbon markets both in Canada and the UK. He received an MBA from the Sauder School of Business and has worked as an analyst and advisor to a number of large companies in the teleco and real estate sectors. 

The Company also announces that Neil Passmore and Abayomi Akinjide will be stepping down as Directors of the Company to focus on their senior corporate activities in the UK. Neil’s decision has been driven by his need to focus on the UK regulated investment bank he runs and reduce overseas listed Board roles. He will remain actively involved as a consultant and continue to support operations in South America including the Company’s mangrove restoration project on Suriname. The Board of Directors of Carbon Done Right express their gratitude for the outstanding contributions Mr. Passmore and Mr. Akinjide have made to the board of the Company.

About Carbon Done Right

Carbon Done Right is an owner and operator of nature-based carbon assets that serves the growing demand for carbon credits from companies seeking to meet their Net Zero goals. The Company achieves this by investing in the exploration, restoration and management of terrestrial and marine systems that can either be protected to enhance the sequestration of greenhouse gases or restored from a degraded status to fully productive ecosystems. The Company’s dedication to environmental stewardship and its robust pipeline of carbon credit projects makes it a trusted partner to the largest buyers of carbon credits in the world, in the fight against climate change. Carbon Done Right deploys capital at risk under various arrangements (including cooperation, assignment, and production sharing agreements) with government engagement in various suitable jurisdictions around the world including Sierra Leone, Yucatan, Guyana and Suriname.

TORONTO, July 08, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialized life sciences company dedicated to the research and development of therapeutics for infectious diseases and medical countermeasures, hereby clarifies its update regarding the research study assessing Bucillamine as a potential treatment for nerve agent exposure. This study is being conducted in collaboration with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence, which is investigating pharmacological compounds, including Bucillamine, capable of mitigating nerve agent-induced brain injury.

VANCOUVER, British Columbia, July 08, 2025 (GLOBE NEWSWIRE) -- Orezone Gold Corporation (TSX: ORE, OTCQX: ORZCF) (the “Company” or “Orezone”) is pleased to announce its Q2-2025 gold production results and stage 1 hard rock expansion construction update at its Bomboré Gold Mine. All dollar amounts are in USD unless otherwise indicated and abbreviation “M” means million.